← Eichor
Study identifier: NCT06804200 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Prospective Validation of AKI Prediction

Condition: Acute Kidney Injury  ·  Sponsor: Adam C Dziorny

PhaseN/A
Planned participants800
Who can joinAll sexes, 30 Days to 18 Years
Healthy volunteersNo

About this study

The purpose of this prospective observational study is to implement, deploy, and quantify accuracy of an existing Pediatric Early AKI Risk Score algorithm. The implementation will be facilitated using a Health Level 7 (HL7) Fast Healthcare Interoperability Resource (FHIR)-based architecture. Investigators will deploy this model and store results in a manner not viewable to the clinical team caring for the patient. To determine the accuracy of the implemented prediction model, Investigators will prospectively identify patients with AKI at 72 hours following ICU admission. Investigators hypothesize that this model will prospectively detect AKI with a sensitivity \>70% and a positive predictive value \>20%, both chosen a priori as 10% improvement over the initial Pediatric AKI Risk Score tool.

This description comes directly from the study's public registry record.

Talk to the study team

Adam C Dziorny, MD, PhD  ·  585-276-3014  ·  adam_dziorny@urmc.rochester.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Golisano Children's Hospital at StrongRochester, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06804200